Louis Navellier’s Top 10 Stock Picks Heading into 2025

3. Eli Lilly and Company (NYSE:LLY)

Navellier & Associates’ Stake Value: $22.12 million

Number of Hedge Funds Holders: 106

Eli Lilly & Company (NYSE:LLY) is a leading global pharmaceutical company that develops, manufactures, and sells a broad range of medications. Founded in 1876, it has grown into one of the world’s largest pharmaceutical firms.

Eli Lilly & Company (NYSE:LLY) saw significant growth in its third-quarter earnings, with a 42% increase in revenue, driven primarily by strong sales of its diabetes and cancer drugs, Mounjaro and Zepbound, which collectively exceeded $3 billion. Earnings per share also rose to $1.18, compared to just $0.10 in the same quarter last year.

Looking forward, the pharma giant raised its revenue guidance to between $45.4 billion and $46 billion, projecting 50% growth in the fourth quarter. The company’s strategic investments, including $2 billion in Ireland and $4.5 billion for the Lilly Medicine Foundry in Indiana, have been crucial to its ongoing expansion.

At the end of October, Truist Securities slightly adjusted its price target for Eli Lilly & Company (NYSE:LLY) shares to $1,029, down from $1,033, while maintaining a Buy rating. The adjustment reflects Eli Lilly’s recent performance and market conditions, with Truist highlighting sustained demand for its type 2 diabetes and obesity treatments as key growth drivers.